![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The vitronectin receptor αvβ3 is a member of a family of membrane bound adhesion receptors that mediate cell–cell and cell–matrix interactions. This integrin recognises extracellular matrix proteins that express the tripeptide Arg-Gly-Asp (RGD). A number of patents and patent applications have recently appeared describing peptidic and non-peptidic αvβ3 antagonists as potential therapeutic agents for the treatment of osteoporosis, cancer, diabetic retinopathy and rheumatoid arthritis. This review covers those issued patents and published patent applications that disclose novel ligands to αvβ3 that have appeared since 1999.